Surrogacy analysis of intermediate end-points for overall survival in randomized controlled trials of rhabdomyosarcoma

Treatment of malignant tumors, such as rhabdomyosarcoma (RMS), can improve overall survival (OS). It is time-consuming and expensive for patients to obtain benefits from randomized controlled trials (RCTs) with OS as the primary end-point. Therefore, another surrogate end-point is necessary; however...

Descripción completa

Detalles Bibliográficos
Autores principales: Kubota, Yuta, Tanaka, Kazuhiro, Kawano, Masanori, Iwasaki, Tatsuya, Itonaga, Ichiro, Tsumura, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653385/
https://www.ncbi.nlm.nih.gov/pubmed/36371419
http://dx.doi.org/10.1038/s41598-022-23944-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653385/
https://www.ncbi.nlm.nih.gov/pubmed/36371419
http://dx.doi.org/10.1038/s41598-022-23944-w

Ejemplares similares